The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma

Abstract

As the global population is aging and survival in multiple myeloma (MM) is increasing, treating older MM patients, redefined as non-transplant eligible (NTE), is becoming more frequent. Yet, treating these patients remains a real challenge especially because of a marked heterogeneity in the population and an increased susceptibility to treatment toxicity. Indeed, the balance between efficacy and safety must be considered at all time throughout the treatment history for these patients. Therefore, younger and older patients were historically treated in a very different way, even though the safety profile of most anti-myeloma drugs has drastically improved over the years. The emergence of immunotherapy (IT) has largely widened the therapeutic options available in MM and above all has allowed a therapy at optimal dose, and therefore optimal activity, for all patients independently of their frailty features, with no increase in safety issues. Among the novel anti-myeloma IT-based agents, anti-CD38 monoclonal antibodies (mAbs) are now becoming the new backbone of treatment for NTE patients, in association with lenalidomide and dexamethasone. Moreover, several new IT-based drugs are currently being developed and investigated either alone or in association; such as new anti-CD38 mAbs, anti-CD38 mAbs with many different combinations, but also the CART cells, bispecific T-cell engager (BiTEs), or antibody drug conjugate (ADC) targeting BCMA. One would expect that immunotherapy will ultimately change and even transform the MM landscape, even for elderly patients. Immunotherapy represents a shift in treatment paradigm in MM as it provides truly efficient drugs with a very favorable safety profile.

Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion

“…For these patients de-escalating steroids after six cycles should be considered. Oral regimens particularly ixazomib based can be given ( 50 , 53 , 54 ).…”

Isatuximab and Belantamab Mafodotin: A Primer to an Evolving Multiple Myeloma Landscape

“…16 Due to its efficacy and tolerability in the RRMM setting, there are several ongoing clinical trials investigating the efficacy of isatuximab in combination with both IMID and PI therapies in patients with NDMM. These include both transplant eligible 39 and transplant ineligible [40][41][42][43] patients. Additionally, isatuximab is currently being investigated as a monotherapy in SMM.…”

Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?

“…Corticosteroids such as dexamethasone and prednisolone, which are utilized for the treatment of lymphoma and leukemia’s are now in phase ¾ clinical trials as mono or combination therapy with other anti-viral agents. Immunomodulatory drugs, such as lenalidomide (Revlimid) and thalidomide generally used for multiple myeloma, lymphoma, graft-versus-host disease, and myelodysplastic syndromes, work through multiple mechanisms such as decreasing TNF-α production and stimulating T cells’ function [ 96 ]. A case report of 45-year-old women with SARS-CoV-2 infection who were treated with thalidomide in combination with low-dose short-term glucocorticoid showed dramatic inhibition of cytokine surge, with an absolute increase in lymphocyte counts and achieved relieve from digestive imbalance [ 97 ].…”